Witness Testimony

Christian Linard, PhD in biochemistry and professor of clinical biochemistry at the Université du Québec à Trois-Rivières, testified regarding the molecular characteristics of mRNA COVID-19 vaccines. He explained the mechanism of mRNA vaccination, describing how lipid nanoparticles deliver synthetic RNA encoding the spike protein into cells for translation. He stated that published analyses indicated variability in mRNA integrity, with some batches containing significant proportions of truncated RNA. He further presented data suggesting variability in spike protein expression among individuals, including differences in antigen production levels and duration, as well as heterogeneity in antibody responses.
Linard described laboratory findings indicating that spike protein isoforms may be produced due to glycosylation and translation variability, and that RNA persistence could last longer than initially expected. He expressed concern about biodistribution studies indicating mRNA presence in multiple organs, including reproductive tissues and breast milk. He also discussed theoretical mechanisms of reverse transcription, stating that while genomic integration would likely be rare, it could not be categorically excluded. He argued that variability in mRNA length and protein expression results in inconsistent dosing and immune responses, potentially contributing to adverse reactions such as thrombocytopenia and autoimmune phenomena.
Beyond molecular analysis, Linard raised concerns about public health definitions and policy, including the classification of individuals as vaccinated only after 14 days, which he argued could affect data interpretation. He criticized political rhetoric directed at vaccine-hesitant individuals and expressed apprehension regarding emerging legislation such as the European Digital Services Act and Canada’s Bill C-11, which he stated could restrict scientific debate and online discourse. He concluded by emphasizing the importance of open scientific discussion, critical thinking, and caution in the deployment of novel biotechnological interventions at population scale.